← Companies|Evommune
Ev

Evommune

Burlingame CAFounded 202115 employees
Private CapbiotechPrivateDermatology
Platform: EVO101 PNP
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
3
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RimanaritideEVO-3568Phase 11Small MoleculePCSK9STINGagPTSD
EVO-481EVO-481Preclinical1RadioligandJAK1CDK4/6iSchizophrenia
EVO-4804EVO-4804Approved2mAbIL-17AMDM2iNB
EVO-1057EVO-1057Phase 33siRNATYK2PARPiHuntington'sT2D
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)
2026-04-12
EVO-4804 Ph3 Readout
NB
Ph3 Readout
2026-05-12
EVO-1057 Ph3 Readout
Huntington's
Ph3 Readout
2027-06-05
EVO-1057 Ph3 Readout
T2D
Ph3 Readout
2027-07-16
EVO-1057 Ph3 Readout
T2D
Ph3 Readout
2028-02-03
EVO-481 Interim
Schizophrenia
Interim
2030-06-08
EVO-4804 Ph3 Readout
NB
Ph3 Readout
2031-04-05
Rimanaritide Interim
PTSD
Interim